Liberty Defense Holdings Ltd. has engaged Global Impact Advisors LLC to enhance its investor relations, strategic communications, and capital markets advisory services. The partnership aims to boost institutional investor awareness, strengthen shareholder relations, and attract new investors. Led by Kevin O'Dowd, a seasoned Wall Street professional, the agreement started on November 6, 2026, with a 12-month term and a monthly retainer of $10,000. This move supports Liberty Defense's growth in providing AI-based detection technology for security screening.
Liberty Defense's investor relations engagement is noted here with Pluang's Technology sector market data as of Nov 13, 2026 06:51 WIB. Among 150 priced Technology-sector US stocks tradable on Pluang, 59 rose and 91 fell today. Notable movers include CLS at USD 259.72 with a 1-day change of +6.92% and 100% buy order activity, QBTS at USD 9.92 down -6.85%, and MSTR at USD 114.36 down -6.53%.
Atlas Energy Corp. completed its first royalty acquisition for $15 million on producing oil and gas assets in Southwest Alberta, funded by cash. The company began generating royalty revenue immediately, earning $141,000 in just seven days post-acquis...
AELO Swiss Academy has transformed into an international airline pilot training organization with bases in Locarno, Lugano, and Cuneo, reflecting over 40 years of aviation heritage. The academy reported a 186% increase in operations in September 2026...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Reviva Pharmaceuticals announced it expects FDA feedback in Q4 2026 on a new formulation of brilaroxazine for its RECOVER-2 Phase 3 trial targeting schizophrenia. The company plans to start a bioequivalence study in Q1 2027 and begin patient enrollme...
